Published in Int J Neuropsychopharmacol on January 06, 2009
Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol (2008) 1.60
Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet (1996) 2.92
Genetic linkage between X-chromosome markers and bipolar affective illness. Nature (1987) 2.44
Rapid tryptophan depletion as a treatment for acute mania: a double-blind, pilot-controlled study. Bipolar Disord (2007) 1.99
Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry (2002) 1.98
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (2008) 1.84
Subtyping major depressive disorder. Psychother Psychosom (2010) 1.76
Association between tridimensional personality questionnaire (TPQ) traits and three functional polymorphisms: dopamine receptor D4 (DRD4), serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT). Mol Psychiatry (2000) 1.74
Transcranial magnetic stimulation in mania: a controlled study. Am J Psychiatry (1998) 1.71
Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature (1988) 1.67
Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry (2005) 1.54
Computerized testing of neurocognitive function in euthymic bipolar patients compared to those with mild cognitive impairment and cognitively healthy controls. Psychother Psychosom (2011) 1.46
Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry (2006) 1.43
Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol (2013) 1.39
Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine. J Clin Psychopharmacol (2016) 1.39
Absence of prion protein mutation in bipolar manic-depressive patients. Br J Psychiatry (1992) 1.36
Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull (2008) 1.26
Trafficked female sex workers awaiting deportation: comparison with brothel workers. Arch Womens Ment Health (2004) 1.20
The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry (2001) 1.20
Ritual female genital surgery among Bedouin in Israel. Arch Sex Behav (1995) 1.15
The motivation and mental health of sex workers. J Sex Marital Ther (2002) 1.14
GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol (2002) 1.13
Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav Pharmacol (2008) 1.12
Treatment of bipolar depression. N Engl J Med (2007) 1.11
Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav Pharmacol (2007) 1.09
Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry (2000) 1.07
Dopamine D4 receptor and serotonin transporter promoter in the determination of neonatal temperament. Mol Psychiatry (1998) 1.05
Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol (2005) 1.05
Knockout mice in understanding the mechanism of action of lithium. Biochem Soc Trans (2009) 1.02
Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm (Vienna) (2004) 1.01
Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry (2012) 1.00
Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res (2001) 1.00
Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual function. Mol Psychiatry (2006) 1.00
Omega 3 fatty acid treatment in autism. J Child Adolesc Psychopharmacol (2009) 1.00
The lessons of platelet monoamine oxidase. Psychol Med (1984) 0.99
Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord (2010) 0.98
Ritual female genital surgery among Ethiopian Jews. Arch Sex Behav (1997) 0.98
Personality and polymorphisms of genes involved in aminergic neurotransmission. Eur J Pharmacol (2000) 0.96
IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology (2007) 0.96
Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of Novelty Seeking. Mol Psychiatry (1998) 0.96
Inositol treatment in psychiatry. Psychopharmacol Bull (1995) 0.96
Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS). Depress Anxiety (2000) 0.96
TPQ in euthymic manic-depressive patients. J Psychiatr Res (1997) 0.95
Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry (1995) 0.95
Transcranial magnetic stimulation induces alterations in brain monoamines. J Neural Transm (Vienna) (1997) 0.95
Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry (1979) 0.95
No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res (2008) 0.95
The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression. Brain Res (1995) 0.94
Slow magnetic stimulation of prefrontal cortex in depression and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (1997) 0.94
Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry (2006) 0.94
Lithium research: state of the art. Biol Psychiatry (1990) 0.94
Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res (2004) 0.93
Impaired heart rate variability in euthymic bipolar patients. Bipolar Disord (2003) 0.93
Dopamine D4 receptor (D4DR) and serotonin transporter promoter (5-HTTLPR) polymorphisms in the determination of temperament in 2-month-old infants. Mol Psychiatry (1999) 0.93
The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord (2001) 0.92
The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord (2000) 0.92
The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. J Pharmacol Exp Ther (1980) 0.91
No association between the serotonin transporter gene regulatory region polymorphism and the Tridimensional Personality Questionnaire (TPQ) temperament of harm avoidance. Mol Psychiatry (1997) 0.91
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry (1997) 0.91
Lithium dosage and inositol levels. Br J Psychiatry (1994) 0.90
The biology of tryptophan depletion and mood disorders. Isr J Psychiatry Relat Sci (2010) 0.90
Epi-inositol regulates expression of the yeast INO1 gene encoding inositol-1-P synthase. Mol Psychiatry (2002) 0.89
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry (2001) 0.89
Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology (1987) 0.89
Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiatry (1991) 0.89
Lithium inhibitable enzymes in postmortem brain of bipolar patients. J Psychiatr Res (2003) 0.89
Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm (Vienna) (2002) 0.88
Biogenic amine-related enzymes and personality variations in normals. Psychol Med (1977) 0.88
GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res (2002) 0.87
Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. Am J Med Genet B Neuropsychiatr Genet (2003) 0.87
The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr Pharm Des (2011) 0.87
5-HT2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet (1997) 0.87
Lithium-pilocarpine seizures as a model for lithium action in mania. Neurosci Biobehav Rev (2007) 0.86
The effect of lithium on expression of genes for inositol biosynthetic enzymes in mouse hippocampus; a comparison with the yeast model. Brain Res Mol Brain Res (2003) 0.86
Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. Int J Neuropsychopharmacol (2008) 0.86
Individual differences and evidence-based psychopharmacology. BMC Med (2012) 0.86
Right prefrontal TMS versus sham treatment of mania: a controlled study. Bipolar Disord (2003) 0.86
Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry (1995) 0.86
Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immun (2011) 0.86
Behavioral evidence for the existence of two pools of cellular inositol. Eur Neuropsychopharmacol (1994) 0.86
Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry (1993) 0.86
Lithium nephrotoxicity. Int J Bipolar Disord (2015) 0.85
Bayesian approach to bipolar guidelines. World J Biol Psychiatry (2010) 0.85
High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.85
Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry (1996) 0.85
Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology (2006) 0.85
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav Brain Res (2001) 0.85
SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Mol Genet Metab (2006) 0.85
Disappearance of female genital mutilation from the Bedouin population of Southern Israel. J Sex Med (2009) 0.85
Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. Am J Med Genet B Neuropsychiatr Genet (2006) 0.83
Human platelet monoamine oxidase changes during the menstrual cycle. Arch Gen Psychiatry (1974) 0.83
Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. Bipolar Disord (2009) 0.83
Inositol treatment raises CSF inositol levels. Brain Res (1993) 0.83
Saga of an adventure gene: novelty seeking, substance abuse and the dopamine D4 receptor (D4DR) exon III repeat polymorphism. Mol Psychiatry (1997) 0.83
Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology (Berl) (1999) 0.83